Wikipedia

Eliezer Huberman

(Redirected from Eliezer (Eli) Huberman)

Eliezer Huberman is an American scietnist who is the founder, scientific director, and CEO of Novadrug LLC, a Chicago-based pharmaceutical firm .[1][2][3] He is currently an adjunct professor in the College of Pharmacy at the University of Illinois.[4]

Huberman's fields of interest include cancer research, cellular differentiation and adult stem cell research.

Education and early career

edit

Huberman received a Master of Science in Clinical Microbiology from Tel-Aviv University (1960-1964) and a Ph.D. in Genetics from the Weizmann Institute of Science (1965-1969).[5] During 1969-1971, Huberman was a Post-Doctoral Fellow at the University of Wisconsin and mentored by the late Professor Charles Heidelberger. In 1968 and 1971 Huberman was a visiting scientist at the U.S. National Cancer Institute.

From 1976 to 1981, Huberman was a senior scientist in the biology division at the U.S. Oak Ridge National laboratory.[6] Prior to this, he was a scientist at the Weizmann Institute, where in time he became a tenured Associate Professor in the Department of Genetics.

Huberman immigrated to the United States, with his family in 1976 to accept an appointment as a cancer researcher at t Oak Ridge. Five years later, he took a senior research position at the U.S. Department of Energy’s Argonne National Laboratory in Lemont, Illinois. There, from 1981 to 1999, Huberman served as Division Director for Biological Research[7] and from 1999 to 2006 as a distinguished Argonne Fellow. He was also a professor at the University of Chicago (1982-1997) in the departments of Microbiology, Molecular Genetics & Cell Biology, and Radiation & Cellular Oncology.

Current work

edit

In 2006, Huberman cofounded Novadrug. He and his team focus their research on developing broad spectrum anti-viral drugs. Novadrug received an NIH grant totalling $245, 000 in 2010 for the development of novel anti-hepatitis C virus drugs from the qualifying therapeutic discovery project program. Huberman holds numerous patents, most recent being a patent for a drug that treats Hepatitis C,[8] but is also promising in the treatment of both Ebola and Marburg disease for which Novadrug has an ongoing collaboration with the U.S. Army. Novadrug has several other patents pending approval.

Academic activities

edit

Huberman has published over 200 scientific papers in journals[9][10][11][12][13][14][15][16][17][18][19] and currently serves as an associate editor of Molecular Carcinogenesis.[20] He was an associate editor of other scientific journals, including Cancer Research,[21] Carcinogenesis and Muagenesis, Molecular and Cellular Differentiation, and Teratogenensis, Pharmacology and Therapeutics. In addition, he is the co-organizer of the ongoing series of the International Charles Heidelberger Symposia on Cancer Research.[22]

Huberman holds various patents including a series involving 5’-monophosphate dehydrogenase,[23][24][25] a target for the antiviral drug ribavirin, as well as one involving a class of drugs that in vitro are effective against human hepatitis C,[26] immunodeficiency, corona and Ebola viruses.[27]

Advisory and committee work

edit

Huberman served on various national and international advisory and review committees including, the U.S. National Academy of Sciences, Environmental Protection agency,[28] Leukemia Research foundation, Massachusetts Institute of Technology, International Agency for Research on Cancer (WHO),[29] Moscow’s Engelhardt Institute of Molecular Biology, National Cancer Institute, and National Institute for Environmental Health. He also served as the Chairman and member of the Scientific Advisory Board for Pharmafrontiers Corporation[30] later, renamed as Opexa Corporation.

Currently, he is a board member of the Charles and Patricia Heidelberger Foundation for Cancer Research and the American Committee for the Weizmann Institute of Science Midwest region.

Distinctions

edit

Huberman is the recipient a visiting professorship at Japan’s Kobe University (2000/2001), an Honorary Doctorate from the Russian Academy of Sciences Engelhardt Institute of Molecular Biology (1997) (10), commendation from the Japanese Society of Pediatric Oncology (1992), Prime Minister Nakasone and University of Tokyo Fellowships for Cancer Research (1986). 2023 will be the 24th symposium, hosted in Chile. Renowned scientists from around the world will attend. In 2022 a biography of Dr. Huberman's life, written by Ellen Brazer, was published. The book I AM Meir's Brother was listed as one of the best Israeli biography books of all time, as featured on CNN, Forbes and Inc – BookAuthority identifies and rates the best books in the world, based on recommendations by thought leaders and experts.

Family life

edit

Huberman is a Holocaust survivor. He was born in Poland in 1939 and moved to Israel in 1950 where he met his wife Lily Huberman (née Ginzburg). They married in 1967 and have two sons.

References

edit
  1. ^ "Midday Fix: Researcher Eliezer Huberman". wgntv.com/. 2014-10-03. Retrieved 12 November 2014.
  2. ^ Gutierrez, Theresa (2014-08-06). "Novadrug,a Chicago Bio-Tech company, works to fight Ebola". abc7chicago.com. Retrieved 12 November 2014.
  3. ^ Wang, Andrew L. (2014-09-18). "Could this Chicago cancer researcher find a treatment for Ebola?". chicagobusiness.com. Retrieved 12 November 2014.
  4. ^ "Biopharmaceutical Sciences Adjunct Faculty". uic.edu. UIC College of Pharmacy. Retrieved 12 November 2014.
  5. ^ "The Graduates" (PDF). weizmann.ac.il/. Weizmann Institute of Science.
  6. ^ "Biology Division Annual Progress Report" (PDF). web.ornl.gov. Archived from the original (PDF) on 21 December 2014. Retrieved 12 November 2014.
  7. ^ "Eliezer Huberman". scopus.com. Retrieved 10 November 2014.
  8. ^ "Patents by Inventor Eliezer Huberman". patents.justia.com/. Retrieved 10 November 2014.
  9. ^ Huberman, Eliezer; Mager, Rivka; Sachs, Leo (1976). "Mutagenesis and transformation of normal cells by chemical carcinogens". Nature. 264 (5584): 360–361. Bibcode:1976Natur.264..360H. doi:10.1038/264360a0. PMID 1034212. S2CID 4208741.
  10. ^ Langenbach, Robert; Freed, Heather J; Raveh, Dina; Huberman, Eliezer (1978). "Cell specificity in metabolic activation of aflatoxin B1 and benzo(a)pyrene to mutagens for mammalian cells". Nature. 276 (5685): 277–280. Bibcode:1978Natur.276..277L. doi:10.1038/276277a0. PMID 714158. S2CID 4276104.
  11. ^ Huberman, Eliezer; Glesne, David; Laouar, Amale (1999). "Involvement of Protein Kinase C-β and Ceramide in Tumor Necrosis Factor-α-induced but Not Fas-induced Apoptosis of Human Myeloid Leukemia Cells". The Journal of Biological Chemistry. 274 (33): 23526–23534. doi:10.1074/jbc.274.33.23526. PMID 10438532.
  12. ^ Collart, Frank; Huberman, Eliezer (1988). "Cloning and Sequence Analysis of the Human and Chinese Hamster Inosine-5'-monophosphate Dehydrogenase cDNA" (PDF). The Journal of Biological Chemistry. 263 (30): 15769–15772. doi:10.1016/S0021-9258(19)37654-9. PMID 2902093. Retrieved 12 November 2014.
  13. ^ Huberman, Eliezer; Xie, Bei; Laouar, Amale (1998). "Fibronectin-mediated Cell Adhesion Is Required for Induction of 92-kDa Type IV Collagenase/Gelatinase (MMP-9) Gene Expression during Macrophage Differentiation". The Journal of Biological Chemistry. 273 (19): 11576–11582. doi:10.1074/jbc.273.19.11576. PMID 9565574.
  14. ^ Chaigne-Delalande, B.; Guidicelli, G.; Couzi, L.; Merville, P.; Mahfouf, W.; Bouchet, S.; Molimard, M.; Pinson, B.; Moreau, J.-F.; Legembre, P. (2008). "The Immunosuppressor Mycophenolic Acid Kills Activated Lymphocytes by Inducing a Nonclassical Actin-Dependent Necrotic Signal". The Journal of Immunology. 181 (11): 7630–7638. doi:10.4049/jimmunol.181.11.7630. PMID 19017951.
  15. ^ Huberman, Eliezer; Callaham, M.F. (1979). "Induction of terminal differentiation in human promyelocytic leukemia cells by tumor-promoting agents". PNAS. 76 (3): 1293–1297. Bibcode:1979PNAS...76.1293H. doi:10.1073/pnas.76.3.1293. PMC 383237. PMID 286311.
  16. ^ Huberman, Eliezer; Zhao, Yong; Glesne, David (2003). "A human peripheral blood monocyte-derived subset acts as pluripotent stem cells". PNAS. 100 (5): 2426–2431. Bibcode:2003PNAS..100.2426Z. doi:10.1073/pnas.0536882100. PMC 151357. PMID 12606720.
  17. ^ Huberman, Eliezer; Sachs, L (1966). "Cell susceptibility to transformation and cytotoxicity by the carcinogenic hydrocarbon benzo[a]pyrene". PNAS. 56 (5): 1123–1129. Bibcode:1966PNAS...56.1123H. doi:10.1073/pnas.56.4.1123. PMC 220015. PMID 5230138.
  18. ^ Huberman, Eliezer; Salzberg, Samuel; Sachs, Leo (1967). "The in vitro induction of an increase in cell multiplication and cellular life span by the water-soluble carcinogen dimethylnitrosamine". PNAS. 59 (1): 77–82. doi:10.1073/pnas.59.1.77. PMC 286004. PMID 5242132.
  19. ^ Huberman, Eliezer; Grover, Philip; Sims, Peter; Marquardt, Hans; Kuroki, Toshio; Heidelberger, Charles (1971). "n Vitro Transformation of Rodent Cells by K-Region Derivatives of Polycyclic Hydrocarbons". PNAS. 68 (6): 1098–1101. Bibcode:1971PNAS...68.1098G. doi:10.1073/pnas.68.6.1098. PMC 389127. PMID 4108174.
  20. ^ "Special Issue: Mechanisms and Targets for Prevention and Treatment of Colorectal Cancer". Molecular Carcinogenesis. 53: i–v. 2014. doi:10.1002/mc.22142.
  21. ^ "Official Journal of the American Association for Cancer Research Editorial Board" (PDF). cancerres.aacrjournals.org. American Association for Cancer Research. Retrieved 12 November 2014.
  22. ^ "The International Charles Heidelberger Symposia on Cancer Research". 20ichscr.uta.cl. Retrieved 12 November 2014.
  23. ^ "Bacterial inosine 5′-monophosphate dehydrogenase ("IMPDH") DNA as a dominant selectable marker in mammals and other eukaryotes". lens.org. Retrieved 12 November 2014.
  24. ^ "Bacterial inosine 5′-monophosphate dehydrogenase ("IMPDH") DNA as a dominant selectable marker in mammals and other eukaryotes". freepatentsonline.com. Retrieved 12 November 2014.
  25. ^ "Methods and materials relating to IMPDH and GMP production". google.com/patents. Retrieved 12 November 2014.
  26. ^ "Spiro hemiaminals for treating viral diseases". freepatentsonline.com. Retrieved 12 November 2014.
  27. ^ Eliezer, Huberman. "Patents by Inventor Eliezer Huberman". patents.justia.com/. Retrieved 10 November 2014.
  28. ^ Bradley, Matthews O.; Bhuyan, Bijoy; Francis, Mary C.; Langenbach, Robert; Peterson, Andrew; Huberman, Eliezer (1981). "Mutagenesis by chemical agents in V79 Chinese hamster cells: A review and analysis of the literature: A report of the gene-tox program". Mutation Research/Reviews in Genetic Toxicology. 87 (2): 81–142. doi:10.1016/0165-1110(81)90029-4. PMID 7035931.
  29. ^ "IARC MONOGRAPHS ON THE EVALUATION OF THE CARCINOGENIC RISK OF CHEMICALS TO HUMANS" (PDF). monographs.iarc.fr/. World Health Organization - International Agency For Research on Cancer. Retrieved 12 November 2014.
  30. ^ "PharmaFrontiers Announces Eliezer Huberman to Chair Scientific Advisory Board". businesswire.com/. BusinessWire. 2005-04-26.
Retrieved from "https://en.wikipedia.org/w/index.php?title=Eliezer_Huberman&oldid=1227941776"